AB Science announced that abstracts reporting the use of Kinavet (masitinib) in the treatment of amyotrophic lateral sclerosis (ALS) were selected for oral presentation at six international meetings in 2017. The abstracts include both preclinical and clinical data. The meetings include: XXIII World Congress of Neurology (WCN 2017) in Kyoto, Japan,…
“If I was a broken clock, would you throw screwdrivers and bolts into my tool shed?” – “Tool Shed” by Chaya Nemiccolo What is emotional intelligence? Patients can easily learn about the traditional aspects of their doctor’s qualifications with a quick internet search. However,…
Managing a chronic illness can be difficult. There are many different medications to take (often at different times), appointments to remember, symptoms to keep track of, and lots of information to absorb. Thankfully, living in a digital age means that there are numerous mobile apps that can help you manage your chronic…
Dear readers, this week my Living Well with ALS column will take a slightly different path down the road of wellness. Because, in the quest of living a balanced life, I’ve learned that humor is something we all need to incorporate into our days. And one of…
Welcome to “The Mighty Mind.” When I was diagnosed with ALS at age 28 in 2015, I felt like I had lost everything. My body, without warning or reason, had turned on me, and that meant the end of so much. My teaching career, and dreams of motherhood and growing…
The National Institutes of Health has awarded $30 million over two years to 13 researchers who are developing three-dimensional models of amyotrophic lateral sclerosis and other diseases. Researchers say the initiative is aimed at tackling a translational science problem: More than 60 percent of therapies prove ineffective in clinical trials of…
NP001 was an injected therapy that was being developed by Neuraltus to slow or stop the progression of ALS. There is currently no evidence of this investigative therapy still being considered a treatment candidate for ALS due to failed results from a Phase 2 trial. How…
Gilenya (TDI-132 or fingolimod) is a therapy currently being researched for the treatment of amyotrophic lateral sclerosis (ALS) by the ALS Therapy Development Institute (ALS TDI). Gilenya was developed by Novartis and is approved for the treatment of multiple sclerosis (MS), another neurodegenerative disorder. How Gilenya…
Everyone suffers from stress from time to time but when you have a chronic disease, stress not only adds to your everyday burden but can often exacerbate the symptoms of your condition. While we can’t avoid stress altogether, there are ways that we help ourselves relax more and not let things…
Scientists have discovered how adult skin cells can be converted into motor neurons without transitioning them through a stem cell state. The findings promise to help researchers better understand motor neuron diseases, such as amyotrophic lateral sclerosis (ALS). The study, “MicroRNAs Induce a Permissive Chromatin Environment that…
